How manufacturers of generics and biosimilars can adapt to EU pharma law changes
Manufacturers of generic and biosimilar medicines should rethink their real world launch, lifecycle and litigation strategies to account for changes to EU pharmaceuticals law expected to be adopted in the coming weeks.
